Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L. Bruce I, et al. Among authors: kirman l. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5445-50. doi: 10.1016/j.bmcl.2012.07.042. Epub 2012 Jul 17. Bioorg Med Chem Lett. 2012. PMID: 22863202
Avoidance of the Ames test liability for aryl-amines via computation.
McCarren P, Bebernitz GR, Gedeck P, Glowienke S, Grondine MS, Kirman LC, Klickstein J, Schuster HF, Whitehead L. McCarren P, et al. Among authors: kirman lc. Bioorg Med Chem. 2011 May 15;19(10):3173-82. doi: 10.1016/j.bmc.2011.03.066. Epub 2011 Apr 3. Bioorg Med Chem. 2011. PMID: 21524589
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.
Lorthiois E, Roache J, Barnes-Seeman D, Altmann E, Hassiepen U, Turner G, Duvadie R, Hornak V, Karki RG, Schiering N, Weihofen WA, Perruccio F, Calhoun A, Fazal T, Dedic D, Durand C, Dussauge S, Fettis K, Tritsch F, Dentel C, Druet A, Liu D, Kirman L, Lachal J, Namoto K, Bevan D, Mo R, Monnet G, Muller L, Zessis R, Huang X, Lindsley L, Currie T, Chiu YH, Fridrich C, Delgado P, Wang S, Hollis-Symynkywicz M, Berghausen J, Williams E, Liu H, Liang G, Kim H, Hoffmann P, Hein A, Ramage P, D'Arcy A, Harlfinger S, Renatus M, Ruedisser S, Feldman D, Elliott J, Sedrani R, Maibaum J, Adams CM. Lorthiois E, et al. Among authors: kirman l. J Med Chem. 2020 Aug 13;63(15):8088-8113. doi: 10.1021/acs.jmedchem.0c00279. Epub 2020 Jul 21. J Med Chem. 2020. PMID: 32551603
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL. Bebernitz GR, et al. Among authors: kirman lc. J Med Chem. 2009 Oct 8;52(19):6142-52. doi: 10.1021/jm900839k. J Med Chem. 2009. PMID: 19746978
Transaminases Provide Key Chiral Building Blocks for the Synthesis of Selective M1/M4 Agonists.
Thomson CG, Boss K, Calhoun A, Fridrich C, Gardinier KM, Hall EC, Jendza K, Kirman L, Labbé-Giguere N, Laumen K, Qian M, Sanyal S, Shultz MD, Snajdrova R, Tan K, Wang KY, Yang F, Gao F, Hong T, Dale E, Kuzmiski B, Ortuno D, Palacios DS. Thomson CG, et al. Among authors: kirman l. ACS Med Chem Lett. 2023 Nov 6;14(12):1692-1699. doi: 10.1021/acsmedchemlett.3c00331. eCollection 2023 Dec 14. ACS Med Chem Lett. 2023. PMID: 38116445